"Johnson & Johnson" suspends its experiments on the "Corona" vaccine

Johnson & Johnson Pharmaceuticals Group announced that it has suspended clinical trials of its experimental COVID-19 vaccine after one of the participants in these trials became ill with an unexplained disease.

"We have temporarily stopped all additional vaccinations in all our clinical trials on an experimental anti-Covid-19 vaccine, including the entire phase III trial, due to an unexplained disease that one of the participants in the study contracted," the group said in a statement.

Johnson & Johnson explained that, according to the decision to suspend clinical trials, an online registration system that it created at the end of September was closed to collect 60,000 volunteers to participate in the third and final phase of clinical trials, and the Independent Patient Safety Committee was also invited to convene to investigate this development.

And the group pointed out in its statement that the occurrence of undesirable events is "something to be expected in any clinical study, especially in large studies."

Johnson & Johnson's protocols state that if any serious adverse event occurs during a study, the study is suspended to indicate whether the event is related to the drug being evaluated and to determine whether the study can be resumed.

The company aimed to gather volunteers in more than 200 locations in the United States and around the world.

The trials are underway in other countries, including Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa.

And the group has become the tenth company to conduct third and final phase experiments globally and fourth in the United States.

Washington has awarded the company $ 1.45 billion in funding under the trials.

Follow our latest local and sports news, and the latest political and economic developments via Google news